Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease حسب John Ryan Kerrigan (20210663)

"…Sickle cell disease (SCD) is a prevalent, life-threatening condition with few treatment options, attributed to a heritable mutation in β-hemoglobin. …"

Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease حسب John Ryan Kerrigan (20210663)

"…Sickle cell disease (SCD) is a prevalent, life-threatening condition with few treatment options, attributed to a heritable mutation in β-hemoglobin. …"

Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease حسب John Ryan Kerrigan (20210663)

"…Sickle cell disease (SCD) is a prevalent, life-threatening condition with few treatment options, attributed to a heritable mutation in β-hemoglobin. …"

Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease حسب John Ryan Kerrigan (20210663)

"…Sickle cell disease (SCD) is a prevalent, life-threatening condition with few treatment options, attributed to a heritable mutation in β-hemoglobin. …"

Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease حسب John Ryan Kerrigan (20210663)

"…Sickle cell disease (SCD) is a prevalent, life-threatening condition with few treatment options, attributed to a heritable mutation in β-hemoglobin. …"

Human Wharton’s jelly-derived mesenchymal stem cells (hWJ-MSCs) and recombinant growth regulated oncogene-alpha (GRO-α) inhibit necroptosis in an mdx mice model. حسب Sang Eon Park (11243760)

Comparison of the Area under the Total Airway Resistance Curve (RL-area) under Different Doses of Methacholine Challenge Test (cmH₂O/mL). حسب Fangwei Xu (11845586)

الموضوعات:

The inhibition of FDNVs internalization in colorectal cells. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Internalization of FDNVs in colorectal cancer and normal colon epithelial cells. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Representative FACS quantitative analyses showing FDNVs-induced apoptosis. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Characterization of FDNVs. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Cytotoxic effects of FDNVs and fingerroot extract on colorectal cancer and normal colon epithelial cell lines. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Size of FDNVs in fractions 7, 8 and 9 using nanoparticle tracking analysis (n = 3). حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Effect of FDNVs on apoptosis-related genes expression. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

IC₅₀ values of FDNVs and fingerroot extract against colorectal cancer cells. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Induction of intracellular ROS and GSH in FDNVs-treated cells. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Total protein concentration of samples from qEV column. حسب Saharut Wongkaewkhiaw (9853495)

الموضوعات:

Table_1_BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.docx حسب Ophélie Champion (16554996)

"…<p>Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory multiple myeloma and consequently presenting limited therapeutic options. We analyzed 13 sPCL for their sensitivity to BH3 mimetics targeting either BCL2 (venetoclax) or BCLXL (A1155463) and showed that 3 sPCL were efficiently killed by venetoclax and 3 sPCL by A1155463. …"

DataSheet_3_BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.docx حسب Ophélie Champion (16554996)

"…<p>Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory multiple myeloma and consequently presenting limited therapeutic options. We analyzed 13 sPCL for their sensitivity to BH3 mimetics targeting either BCL2 (venetoclax) or BCLXL (A1155463) and showed that 3 sPCL were efficiently killed by venetoclax and 3 sPCL by A1155463. …"

DataSheet_1_BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.docx حسب Ophélie Champion (16554996)

"…<p>Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory multiple myeloma and consequently presenting limited therapeutic options. We analyzed 13 sPCL for their sensitivity to BH3 mimetics targeting either BCL2 (venetoclax) or BCLXL (A1155463) and showed that 3 sPCL were efficiently killed by venetoclax and 3 sPCL by A1155463. …"